Phase II trial of merbarone in pancreatic carcinoma. A Southwest Oncology Group study
- PMID: 8328410
- DOI: 10.1097/00000421-199308000-00010
Phase II trial of merbarone in pancreatic carcinoma. A Southwest Oncology Group study
Abstract
Twenty-nine patients with advanced pancreatic adenocarcinoma were treated with merbarone, utilizing a daily intravenous schedule for 5 days. Only two partial responses of short duration were observed. The major toxicities were renal, with an increase in creatinine or proteinuria in 17 patients, and mild to moderate nausea and vomiting seen in 22 patients. Merbarone in this dose and schedule has minimal activity in pancreatic cancer.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical